Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Istodax
(United States) [Available]Synonyms :
Romidepsin, Romidepsina, Romidepsine, Romidepsinum
Class :
Antineoplastics and HDAc Inhibitors
Brand Name :
Istodax
(United States) [Available]Synonyms :
Romidepsin, Romidepsina, Romidepsine, Romidepsinum
Class :
Antineoplastics and HDAc Inhibitors
Dosage Forms & Strengths  Â
Injection, lyophilized powder for reconstitution  Â
10 mg  Â
5 mg per ml  Â
Indicated for the treatment of CTCL and peripheral T-cell lymphoma (PTCL) in patients who have received at least one before systemic therapy :
14
mg/m^2
Intravenous (IV)
over 4 hr
on days 1, 8, and 15 for a 28-day cycle course
Continue to repeat the cycle every 28 days till the patient's disease progression or intolerable toxicity occurs
Indicated for the treatment of CTCL and peripheral T-cell lymphoma (PTCL) in patients who have received at least one before systemic therapy :
14
mg/m^2
Intravenous (IV)
over 4 hr
on days 1, 8, and 15 for a 28-day cycle course
Continue to repeat the cycle every 28 days till the patient's disease progression or intolerable toxicity occurs
when both drugs are combined, there may be an increased level or effect of romidepsin by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, there may be an increased level or effect of romidepsin by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, both increase the QTC interval  
when both drugs are combined, both increase the QTC interval  
when both drugs are combined, there may be an increased level or effect of romidepsin by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, there may be a reduced level or effect of romidepsin by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, both increase the QTC interval  
when both drugs are combined, both increase the QTC interval  
when both drugs are combined, there may be an increased level or effect of romidepsin by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, there may be a reduced level or effect of romidepsin by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, there may be a reduced level or effect of romidepsin by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, there may be a reduced level or effect of romidepsin by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, both increase the QTC interval  
when both drugs are combined, there may be an increased level or effect of romidepsin by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, there may be an increased level or effect of romidepsin by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, both increase the QTC interval  
when both drugs are combined, there may be a reduced level or effect of romidepsin by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, there may be an increased level or effect of romidepsin by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, there may be an increased level or effect of romidepsin by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, there may be a reduced level or effect of romidepsin by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, both increase the QTC interval  
when both drugs are combined, there may be an increased level or effect of romidepsin by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, both increase the QTC interval  
when both drugs are combined, both increase the QTC interval  
when both drugs are combined, both increase the QTC interval  
when both drugs are combined, there may be a reduced level or effect of romidepsin by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, both increase the QTC interval  
QTc interval is increased both by lenvatinib and romidepsin
CYP3A strong enhancers of the small intestine may reduce the bioavailability of romidepsin
when used together, entrectinib and romidepsin both increase the QTc interval
when used together, encorafenib and romidepsin both increase the QTc interval
histone deacetylase inhibitors increase the toxicity of taurursodiol
may increase the QTc interval when combined
may have an increasingly adverse effect when combined with taurursodiol
may have an increasingly adverse effect when combined with taurursodiol
when both drugs are combined, both increase the QTC interval  
when both drugs are combined, both increase the QTC interval  
when both drugs are combined, both increase the QTC interval  
when both drugs are combined, both increase the QTC interval  
when both drugs are combined, there may be a decreased effects of ethinylestradiol by receptor binding competition  
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be an increased level or effect of romidepsin by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, both increase the QTC interval  
when both drugs are combined, there may be an increased level or effect of romidepsin by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, both increase the QTC interval  
when both drugs are combined, both increase the QTC interval  
when both drugs are combined, both increase the QTC interval  
when both drugs are combined, both increase the QTC interval  
when both drugs are combined, both increase the QTC interval  
when both drugs are combined, both increase the QTC interval 
It may enhance the risk of adverse effects when combined with Enzymes
romidepsin: they may enhance the serum concentration of glycoprotein Inhibitors
Romidepsin is a prodrug that becomes active inside the cell, where it is reduced to release a free thiol group. This active form binds to zinc ions in the catalytic domain of class I and II histone deacetylase (HDAC) enzymes, thereby inhibiting their enzymatic activity. In many tumors, HDACs are overexpressed while histone acetyltransferases (HATs) are downregulated or mutated, leading to epigenetic silencing of tumor suppressor genes. By inhibiting HDACs, romidepsin restores acetylation levels, reactivates suppressed regulatory genes, and induces cell cycle arrest and apoptosis in cancer cells.Â
Adverse drug reactions: Â
Frequency defined Â
>10% Â
Asthenia Â
Anemia Â
Anorexia Â
Constipation Â
Diarrhea Â
Hypomagnesemia Â
Nausea Â
Neutropenia Â
Thrombocytopenia Â
Vomiting Â
<10% Â
EKG changes Â
Exfoliative dermatitis Â
Hypotension Â
Hypocalcemia Â
Hypoalbuminemia Â
Hypokalemia Â
Hyperglycemia Â
Hyponatremia Â
Increased LFTs Â
Leukopenia Â
Lymphopenia Â
Pruritus Â
NoneÂ
ContraindicationÂ
HypersensitivityÂ
CautionsÂ
QT Prolongation: Ensure potassium and magnesium levels are normal before administration.Â
Tumor Lysis Syndrome: Monitor closely in patients with advanced disease or high tumor burden.Â
Hematologic Toxicity: Regularly assess blood counts; interrupt or discontinue treatment if severe thrombocytopenia, leukopenia, or anemia occurs.Â
Serious Infections: Potential for life-threatening infections (e.g., pneumonia, sepsis, viral reactivation) within 30 days post-treatment, especially in those with prior monoclonal antibody therapy or bone marrow involvement.Â
Viral Reactivation: Monitor patients with prior hepatitis B infection and consider antiviral prophylaxis; Epstein-Barr virus reactivation, including fatal liver failure, has been reported.  Â
Pregnancy warnings:   Â
Breastfeeding warnings:Â
Pregnancy Categories:     Â
Romidepsin is an HDAC inhibitor used to treat cutaneous and peripheral T-cell lymphomas. By blocking HDAC enzymes, it prevents histone deacetylation, leading to changes in gene expression that promote cell cycle arrest and apoptosis in cancer cells.Â
PharmacokineticsÂ
AbsorptionÂ
Romidepsin exhibits linear pharmacokinetics at standard therapeutic doses.Â
DistributionÂ
It has a volume of distribution of 44.5 L and is highly protein bound in plasma (92%–94%).Â
MetabolismÂ
Romidepsin undergoes extensive hepatic metabolism, primarily via CYP3A4, with minor contributions from CYP3A5, CYP1A1, CYP2B6, and CYP2C19.Â
Elimination/ExcretionÂ
The elimination route is not well-defined. It has a clearance rate of 8.4 L/h and a half-life of approximately 3 hours.Â
PharmacodynamicsÂ
Romidepsin is a prodrug that becomes active inside cells, where its metabolite releases a free thiol group. This group binds to zinc ions in class I and II HDAC enzymes, inhibiting their activity.Â
Infuse intravenously over 4 hours using a volumetric pump. Use PVC, EVA, PE infusion bags, or glass bottles. Follow cytotoxic drug handling and disposal guidelines.Â
StorageÂ
Unopened vials: Store at 20–25°C (68–77°F), excursions allowed between 15–30°C (59–86°F); protect from light.Â
Reconstituted vials: Stable for 8 hours at room temperature.Â
Diluted solutions: Stable at room temperature for up to 24 hours.Â
Generic Name: romidepsinÂ
Pronounced: roe-mi-DEP-sinÂ
Why do we use romidepsin? Â
Romidepsin injection is used to treat cutaneous T-cell lymphoma (CTCL) in patients who have previously received at least one other treatment.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
